Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.

Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities

The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.

Bruker Wins Major UC Berkeley Order For Advanced Research Systems

Bruker Corporation (NASDAQ:BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center.

LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.

UBS Maintains Neutral on Bruker, Raises Price Target to $65